Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Illumina, Inc. - Common Stock
(NQ:
ILMN
)
190.89
-1.75 (-0.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Illumina, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Waters Q2 Earnings Call Highlights
↗
August 09, 2026
Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic...
Via
MarketBeat
Topics
Earnings
Biotech AI Retail Solutions Market to Reach USD 7.12 Billion by 2034
↗
August 07, 2026
According to a new report from Intel Market Research, the global Biotech AI Retail Solutions market was valued at USD 3.45 billion in 2025 and is projected
Via
Talk Markets
Topics
Artificial Intelligence
5 Must-Read Analyst Questions From Illumina’s Q2 Earnings Call
August 06, 2026
Illumina’s second quarter results reflected strong execution in its core clinical sequencing business, with management highlighting robust demand from U.S. a...
Via
StockStory
Topics
Earnings
Illumina (NASDAQ:ILMN) Beats Q2 Estimates but Shares Slide 6% After-Hours
↗
July 30, 2026
Via
Chartmill
Illumina (NASDAQ:ILMN) Scores Perfect Technical Rating and High Setup Quality for Breakout Trade
↗
July 30, 2026
Via
Chartmill
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
↗
August 05, 2026
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 3.84% on an annualized basis producing an average annual return of 13.26%. Currently, Illumina has a market capitalization...
Via
Benzinga
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
August 04, 2026
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after market close. Here’s what to expect. 10x Genomics beat anal...
Via
StockStory
PacBio (PACB) To Report Earnings Tomorrow: Here Is What To Expect
August 03, 2026
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results this Wednesday afternoon. Here’s what you need to know. PacBio mis...
Via
StockStory
Illumina (ILMN) Q2 2026 Earnings Call Transcript
↗
August 03, 2026
Clinical momentum and NovaSeq X placements drive revenue guidance raise.
Via
The Motley Fool
Topics
Earnings
3 Cash-Producing Stocks That Concern Us
August 03, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?
↗
August 01, 2026
The developer of blood-based cancer tests still has a bright future.
Via
The Motley Fool
Illumina Q2 Earnings Call Highlights
↗
July 31, 2026
Illumina (NASDAQ:ILMN) raised its 2026 revenue and earnings outlook after reporting second-quarter results that exceeded its expectations, supported by clinical sequencing demand, elevated NovaSeq X...
Via
MarketBeat
Topics
Earnings
ILMN Q2 Deep Dive: Clinical Strength, Platform Expansion, and Strategic Focus Drive Guidance Lift
July 31, 2026
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s...
Via
StockStory
Illumina (ILMN) Q2 2026 Earnings Call Transcript
↗
July 30, 2026
Clinical momentum and NovaSeq X placements drive revenue guidance raise.
Via
The Motley Fool
Topics
Earnings
Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations
July 30, 2026
Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. ...
Via
StockStory
Illumina Earnings: What To Look For From ILMN
July 28, 2026
Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday after market close. Here’s what to expect. Illumina beat analysts’ ...
Via
StockStory
Topics
Artificial Intelligence
3 Healthcare Stocks with Questionable Fundamentals
July 23, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...
Via
StockStory
3 Profitable Stocks We Find Risky
July 22, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.
↗
July 13, 2026
The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers.
Via
The Motley Fool
2 Mooning Stocks Worth Investigating and 1 We Avoid
July 09, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Via
StockStory
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN)
July 06, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Economy
1 High-Flying Stock with Solid Fundamentals and 2 We Find Risky
July 06, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via
StockStory
Topics
Energy
Prediction: Grail Stock Will Skyrocket to $100 in 1 Year
↗
July 02, 2026
The cancer test maker still has a bright future.
Via
The Motley Fool
3 Mid-Cap Stocks That Concern Us
July 02, 2026
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Via
StockStory
Why Illumina (ILMN) Stock Is Down Today
June 30, 2026
What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 1.9% in the afternoon session after Swiss drugmaker Roche launched a next-generation ge...
Via
StockStory
Why Illumina (ILMN) Stock Is Trading Up Today
June 24, 2026
What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to ...
Via
StockStory
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
June 16, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via
StockStory
Topics
Artificial Intelligence
Why Grail Could Be the Sleeper Stock Everyone's About to Notice
↗
June 08, 2026
Grail is on a quest to win in a $50 billion market.
Via
The Motley Fool
CalTek Staffing Earns Spot on Two Forbes 2026 Best Of Lists
June 04, 2026
Via
AB Newswire
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
↗
June 04, 2026
The cancer test maker could still have a bright future.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.